{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:17:26Z","timestamp":1783430246151,"version":"3.54.6"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Emerging Leader Investigator Fellowship from the National Health and Medical Research Council","award":["APP2008119"],"award-info":[{"award-number":["APP2008119"]}]},{"DOI":"10.13039\/100009727","name":"Hospital Research Foundation","doi-asserted-by":"publisher","award":["2023-S-DTFA-005"],"award-info":[{"award-number":["2023-S-DTFA-005"]}],"id":[{"id":"10.13039\/100009727","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021954","name":"Tour De Cure","doi-asserted-by":"publisher","award":["RSP-117-FY2023"],"award-info":[{"award-number":["RSP-117-FY2023"]}],"id":[{"id":"10.13039\/501100021954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2030913"],"award-info":[{"award-number":["APP2030913"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beat Cancer Research Fellowship from the Cancer Council South Australia"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sex is a recognized modifier of physiology, immunity, and social exposures, yet its independent association with survival and adverse event prognosis in contemporary anticancer therapy remains poorly defined. The aim of the present study was to assess the association between patient sex and overall survival, progression-free survival, and grade 3 or greater adverse events across a pooled individual participant data meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Individual participant data supporting US Food and Drug Administration approval of anticancer medicines for solid tumors between 2011 and 2021 were accessed through the Vivli and Yale University Open Data Access data sharing platforms. A 2-stage random-effects meta-analysis approach was employed using Cox proportional hazards regression to estimate sex-based prognostic differences in overall survival, progression-free survival, and grade 3 or greater adverse events. Analyses were adjusted for key baseline covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In a pooled cohort of 20\u200a806 participants from 39 phase 2 and 3 trials supporting Food and Drug Administration approvals of anticancer medicines for advanced solid tumors, across 12 tumor types, female sex was associated with statistically significantly improved overall survival (hazard ratio\u2009=\u20090.79, 95% CI\u2009=\u20090.73 to 0.85; P\u2009&amp;lt;\u2009.001) and progression-free survival (hazard ratio\u2009=\u20090.84, 95% CI\u2009=\u20090.79 to 0.89; P\u2009&amp;lt;\u2009.001). Conversely, female patients experienced a higher risk of grade 3 or greater adverse events (hazard ratio\u2009=\u20091.12, 95% CI\u2009=\u20091.07 to 1.18; P\u2009&amp;lt;\u2009.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the largest analysis of individual participant data from trials supporting Food and Drug Administration drug approvals, we found that female patients had a 21% lower risk of death and a 16% lower risk of progression but a 12% higher risk of severe adverse events. These findings highlight the value of individual participant data sharing and the importance of sex-stratified evidence for risk stratification, dose optimization, and patient counseling.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djag046","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:44:11Z","timestamp":1770813851000},"page":"1219-1228","source":"Crossref","is-referenced-by-count":0,"title":["Sex-based prognosis in industry-sponsored advanced solid tumor trials: an individual participant data meta-analysis of survival and adverse events"],"prefix":"10.1093","volume":"118","author":[{"given":"Rakchha","family":"Chhetri","sequence":"first","affiliation":[{"name":"College of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University , Adelaide, SA,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3262-5374","authenticated-orcid":false,"given":"Natansh D","family":"Modi","sequence":"additional","affiliation":[{"name":"Clinical and Health Sciences, University of South Australia , Adelaide, SA,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0855-5081","authenticated-orcid":false,"given":"Bradley D","family":"Menz","sequence":"additional","affiliation":[{"name":"College of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University , Adelaide, SA,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4588-2688","authenticated-orcid":false,"given":"Erik","family":"Cornelisse","sequence":"additional","affiliation":[{"name":"College of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University , Adelaide, SA,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1054-762X","authenticated-orcid":false,"given":"David","family":"Postma","sequence":"additional","affiliation":[{"name":"College of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University , Adelaide, SA,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9263-8540","authenticated-orcid":false,"given":"Nicole M","family":"Kuderer","sequence":"additional","affiliation":[{"name":"Advanced Cancer Research Group , Kirkland, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0823-8086","authenticated-orcid":false,"given":"Gary H","family":"Lyman","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Center , Seattle, WA,","place":["United States"]},{"name":"Division of Medical Oncology, Duke University School of Medicine , Durham, NC,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1320-3830","authenticated-orcid":false,"given":"Sandra M","family":"Swain","sequence":"additional","affiliation":[{"name":"Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center and Genetic Medicine, MedStar Health , Washington, DC,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5259-5198","authenticated-orcid":false,"given":"Lee X","family":"Li","sequence":"additional","affiliation":[{"name":"College of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University , Adelaide, SA,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4182-065X","authenticated-orcid":false,"given":"Ahmad Y","family":"Abuhelwa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah , Sharjah,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3725-793X","authenticated-orcid":false,"given":"Ross A","family":"McKinnon","sequence":"additional","affiliation":[{"name":"College of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University , Adelaide, SA,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4815-0994","authenticated-orcid":false,"given":"Sina","family":"Vatandoust","sequence":"additional","affiliation":[{"name":"College of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University , Adelaide, SA,","place":["Australia"]},{"name":"Flinders Centre for Innovation in Cancer, Department of Medical Oncology, Flinders Medical Centre, Flinders University , Bedford Park, SA,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9923-5149","authenticated-orcid":false,"given":"Ganessan","family":"Kichenadasse","sequence":"additional","affiliation":[{"name":"College of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University , Adelaide, SA,","place":["Australia"]},{"name":"Flinders Centre for Innovation in Cancer, Department of Medical Oncology, Flinders Medical Centre, Flinders University , Bedford Park, SA,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8946-3954","authenticated-orcid":false,"given":"Andrew","family":"Rowland","sequence":"additional","affiliation":[{"name":"College of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University , Adelaide, SA,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1999-866X","authenticated-orcid":false,"given":"Michael J","family":"Sorich","sequence":"additional","affiliation":[{"name":"College of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University , Adelaide, SA,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7652-4378","authenticated-orcid":false,"given":"Ashley M","family":"Hopkins","sequence":"additional","affiliation":[{"name":"College of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University , Adelaide, SA,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"2026070708463234000_djag046-B1","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1200\/JCO.2018.78.3290","article-title":"Sex differences in efficacy and toxicity of systemic treatments: an undervalued issue in the era of precision oncology","volume":"36","author":"\u00d6zdemir","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026070708463234000_djag046-B2","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1089\/jwh.2019.8247","article-title":"Sex as a biological variable: a 5-year progress report and call to action","volume":"29","author":"Arnegard","year":"2020","journal-title":"J Womens Health (Larchmt)"},{"key":"2026070708463234000_djag046-B3","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1038\/s41467-024-46945-x","article-title":"Outcome differences by sex in oncology clinical trials","volume":"15","author":"Kammula","year":"2024","journal-title":"Nat Commun"},{"key":"2026070708463234000_djag046-B4","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1007\/s12094-025-03893-2","article-title":"Sex-related differences in the efficacy and toxicity of cancer treatments","volume":"27","author":"Santaballa Bertr\u00e1n","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"2026070708463234000_djag046-B5","doi-asserted-by":"crossref","first-page":"100152","DOI":"10.1016\/j.crphar.2022.100152","article-title":"Sex differences in drug effects and\/or toxicity in oncology","volume":"4","author":"Rakshith","year":"2023","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"2026070708463234000_djag046-B6","year":"2025"},{"key":"2026070708463234000_djag046-B7","year":"2025"},{"key":"2026070708463234000_djag046-B8","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/jnci\/djac092","article-title":"An evaluation of sex- and gender-based analyses in oncology clinical trials","volume":"114","author":"Hall","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"2026070708463234000_djag046-B9","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1007\/s00432-022-04270-0","article-title":"Do female and male patients derive similar benefits from approved systemic oncology therapies? A systematic review and meta-analysis","volume":"149","author":"Arciero","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026070708463234000_djag046-B10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/cncr.35035","article-title":"Meta-analysis of sex and racial subgroup participation rates and differential treatment effects for trials in solid tumor malignancies leading to US Food and Drug Administration registration between 2010 and 2021","volume":"130","author":"Wilson","year":"2024","journal-title":"Cancer"},{"key":"2026070708463234000_djag046-B11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients\u2019 sex: a systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026070708463234000_djag046-B12","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1001\/jama.2016.13995","article-title":"Consideration of sex differences in medicine to improve health care and patient outcomes","volume":"316","author":"Legato","year":"2016","journal-title":"JAMA"},{"key":"2026070708463234000_djag046-B13","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1158\/1055-9965.EPI-11-0246","article-title":"Sex disparities in cancer mortality and survival","volume":"20","author":"Cook","year":"2011","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2026070708463234000_djag046-B14","doi-asserted-by":"crossref","first-page":"e000796","DOI":"10.1136\/esmoopen-2020-000796","article-title":"Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer","volume":"5","author":"Mederos","year":"2020","journal-title":"ESMO Open"},{"key":"2026070708463234000_djag046-B15","doi-asserted-by":"crossref","first-page":"53668","DOI":"10.18632\/oncotarget.10696","article-title":"Impact of sex, age, and ethnicity\/race on the survival of patients with rectal cancer in the United States from 1988 to 2012","volume":"7","author":"Berger","year":"2016","journal-title":"Oncotarget"},{"key":"2026070708463234000_djag046-B16","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s10147-015-0868-6","article-title":"Gender differences in colorectal cancer survival in Japan","volume":"21","author":"Kotake","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"2026070708463234000_djag046-B17","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s11605-019-04304-y","article-title":"Gender differences in gastric cancer survival: 99,922 cases based on the SEER database","volume":"24","author":"Li","year":"2020","journal-title":"J Gastrointest Surg"},{"key":"2026070708463234000_djag046-B18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00262-024-03719-0","article-title":"Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations","volume":"73","author":"Incorvaia","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"2026070708463234000_djag046-B19","doi-asserted-by":"crossref","first-page":"404","DOI":"10.4143\/crt.2023.784","article-title":"Impact of patient sex on adverse events and unscheduled utilization of medical services in cancer patients undergoing adjuvant chemotherapy: a multicenter retrospective cohort study","volume":"56","author":"Choi","year":"2024","journal-title":"Cancer Res Treat"},{"key":"2026070708463234000_djag046-B20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2020.06.005","article-title":"Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: a pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03)","volume":"137","author":"Athauda","year":"2020","journal-title":"Eur J Cancer"},{"key":"2026070708463234000_djag046-B21","doi-asserted-by":"crossref","first-page":"e1148","DOI":"10.1634\/theoncologist.2019-0094","article-title":"Sex differences in tolerability to anti-programmed cell death protein 1 therapy in patients with metastatic melanoma and non-small cell lung cancer: are we all equal?","volume":"24","author":"Duma","year":"2019","journal-title":"Oncologist"},{"key":"2026070708463234000_djag046-B22","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.21.02377","article-title":"Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials","volume":"40","author":"Unger","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026070708463234000_djag046-B23","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/jnci\/djaa124","article-title":"Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34\u2009640 patients in the ACCENT database","volume":"113","author":"Wagner","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2026070708463234000_djag046-B24","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2018.1080","article-title":"association of patient sex with chemotherapy-related toxic effects: a retrospective analysis of the PETACC-3 trial conducted by the EORTC gastrointestinal group","volume":"4","author":"Cristina","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026070708463234000_djag046-B25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s11096-022-01395-7","article-title":"Sex differences in immune-related adverse events with immune checkpoint inhibitors: data mining of the FDA adverse event reporting system","volume":"44","author":"Chen","year":"2022","journal-title":"Int J Clin Pharm"},{"key":"2026070708463234000_djag046-B26","doi-asserted-by":"crossref","first-page":"28309","DOI":"10.1038\/s41598-024-71746-z","article-title":"Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis","volume":"14","author":"Vitale","year":"2024","journal-title":"Sci Rep"},{"key":"2026070708463234000_djag046-B27","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/jnci\/djab035","article-title":"Association between sex and immune-related adverse events during immune checkpoint inhibitor therapy","volume":"113","author":"Jing","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2026070708463234000_djag046-B28","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/s12916-023-03113-0","article-title":"A 10-year update to the principles for clinical trial data sharing by pharmaceutical companies: perspectives based on a decade of literature and policies","volume":"21","author":"Modi","year":"2023","journal-title":"BMC Med"},{"key":"2026070708463234000_djag046-B29","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2022.2867","article-title":"Audit of data sharing by pharmaceutical companies for anticancer medicines approved by the US Food and Drug Administration","volume":"8","author":"Modi","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026070708463234000_djag046-B30","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1001\/jamaoncol.2023.3996","article-title":"Heterogeneity and utility of pharmaceutical company sharing of individual-participant data packages","volume":"9","author":"Hopkins","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026070708463234000_djag046-B31","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1200\/JCO.24.00539","article-title":"Clinical study report and individual participant data transparency for US Food and Drug Administration-approved anticancer drugs: a call for systematic data availability","volume":"42","author":"Modi","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026070708463234000_djag046-B32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12916-018-1154-z","article-title":"Data sharing from pharmaceutical industry sponsored clinical studies: audit of data availability","volume":"16","author":"Hopkins","year":"2018","journal-title":"BMC Med"},{"key":"2026070708463234000_djag046-B33","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/sim.7141","article-title":"Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ","volume":"36","author":"Burke","year":"2017","journal-title":"Stat Med"},{"key":"2026070708463234000_djag046-B34","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejca.2017.07.013","article-title":"Sex differences in cancer risk and survival: a Swedish cohort study","volume":"84","author":"Radkiewicz","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026070708463234000_djag046-B35","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/jjco\/hyad025","article-title":"Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors","volume":"53","author":"Nemoto","year":"2023","journal-title":"Jpn J Clin Oncol"},{"key":"2026070708463234000_djag046-B36","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.ejca.2008.11.008","article-title":"The advantage of women in cancer survival: an analysis of EUROCARE-4 data","volume":"45","author":"Micheli","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026070708463234000_djag046-B37","first-page":"1059","article-title":"Differences in cancer survival by sex: a population-based study using cancer registry data","volume":"29","author":"Afshar","year":"2018","journal-title":"Cancer Causes Control"},{"key":"2026070708463234000_djag046-B38","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"2026070708463234000_djag046-B39","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br J Clin Pharmacol"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag046\/66938196\/djag046.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/7\/1219\/66938196\/djag046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/7\/1219\/66938196\/djag046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:47:46Z","timestamp":1783428466000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/118\/7\/1219\/8487769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":39,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,2,16]]},"published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djag046","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,2,16]]}}}